semaglutide fda news FBI issues safety warning about counterfeit versions of weight loss drug U.S. FDA finds no evidence

Regarding libido and sexual function: some individuals using GLP-1 receptor agonists and related weight-loss medicines have anecdotally reported changes in libido both increases and decreases across online patient communities and in broader discussions about the drug class

When you eat less and burn more calories than you consume, your body mobilizes stored fat for energy

doi: 10.1016/j.neurobiolaging.2008.04.002 166 ParkHRParkMChoiJParkKYChungHYLeeJ

Phase two, or methylation, is where the liver prepares these metabolites for elimination by adding a methyl group

It is linked to elevated levels of fibrinogen and C-reactive protein, diabetes, insulin resistance, dyslipidemia, and hypertension, all of which raise the risk of CVD events ( It is less evident how GLP-1 agonists directly affect arrhythmias, some studies suggest they may reduce frequency of arrythmias because their favorable effects on metabolism and over all cardiovascular health

For these reasons, GLP-1 analogues have been FDA-approved for treatment of obesity and diabetes, Dr